Targeting this pathway with the AURKA inhibitor PHA739358 in combination with Olaparib markedly suppressed tumour growth in both cell line derived and patient-derived xenograft models, underscoring a mechanistic and therapeutic convergence between AURKA and PARPi in MYCN-driven malignancies (Zhang et al., 2018). This evidence concerns the gene MYCN and neoplasm.